Antibody–cytokine fusion proteins: applications in cancer therapy

Bibliography

• Janeway CA, Travers P, Walport M, Schlomchick M. Chapter 4: The generation of lymphocyte antigen receptors. In: Immunobiology: The Immune System in Health and Disease. Lawrwnce E, editor. Garland Publishing, New York; 2005. p. 135-64
   Google Scholar
• Schaedel O, Reiter Y. Antibodies and their fragments as anti-cancer agents. Curr Pharm Des 2006;12:363-78
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007;19:239-45
   PubMed Web of Science ®Google Scholar
• Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005;20:17-29
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL. Myeloma expression systems. J Immunol Methods 2002;261:1-20
   PubMed Web of Science ®Google Scholar
• Penichet ML, Morrison SL. Design and engineering human forms of monoclonal antibodies. Drug Develop Res 2004;61:121-36
   Web of Science ®Google Scholar
• Lubeck MD, Kimoto Y, Steplewski Z, Koprowski H. Killing of human tumor cell lines by human monocytes and murine monoclonal antibodies. Cell Immunol 1988;111:107-17
   PubMed Web of Science ®Google Scholar
• Dillman RO. The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy. Curr Pharm Biotechnol 2001;2:293-300
   PubMedGoogle Scholar
• Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56:226-43
   PubMed Web of Science ®Google Scholar
• Reilly RM, Sandhu J, Alvarez-Diez TM, et al. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-42
   PubMed Web of Science ®Google Scholar
• Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992;327:736
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis. Drugs Aging 1998;12:139-48
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851-5
   PubMed Web of Science ®Google Scholar
• Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51
   PubMedGoogle Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, et al.: Replacing the complementary-determining regions in a human antibody with those from a mouse. Nature 1986;321:522-5
   PubMed Web of Science ®Google Scholar
• Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006;11(Suppl 1):4-12
   PubMed Web of Science ®Google Scholar
• Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999;231:11-23
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Caskey HM, Teale C, et al. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci USA 1989;86:6709-13
   PubMed Web of Science ®Google Scholar
• Tomizuka K, Shinohara T, Yoshida H, et al. Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 2000;97:722-7
   PubMed Web of Science ®Google Scholar
• Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228:1315-7
   PubMed Web of Science ®Google Scholar
• Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879-83
   PubMed Web of Science ®Google Scholar
• Power BE, Caine JM, Burns JE, et al. Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. Cancer Immunol Immunother 2001;50:241-50
   PubMed Web of Science ®Google Scholar
• Albrecht H, Denardo SJ. Recombinant antibodies: from the laboratory to the clinic. Cancer Biother Radiopharm 2006;21:285-304
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-36
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46
   PubMed Web of Science ®Google Scholar
• Presta L. Antibody engineering for therapeutics. Curr Opin Struct Biol 2003;13:519-25
   PubMed Web of Science ®Google Scholar
• Hunter CA, Reiner SL. Cytokines and T cells in host defense. Curr Opin Immunol 2000;12:413-8
   PubMed Web of Science ®Google Scholar
• Masztalerz A, Van Rooijen N, Den Otter W, Everse LA. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother 2003;52:235-42
   PubMed Web of Science ®Google Scholar
• Munn DH, Cheung NK. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987;47:6600-5
   PubMed Web of Science ®Google Scholar
• Parmiani G, Rivoltini L, Andreola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett 2000;74:41-4
   PubMed Web of Science ®Google Scholar
• Emminger W, Emminger-Schmidmeier W, Peters C, et al. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blut 1990;61:219-21
   PubMedGoogle Scholar
• Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology 2002;16:11-20
   PubMed Web of Science ®Google Scholar
• Stern AC, Jones TC. The side-effect profile of GM-CSF. Infection 1992;20(Suppl 2):S124-7
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-8
   PubMed Web of Science ®Google Scholar
• Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92:1684-8
   PubMed Web of Science ®Google Scholar
• Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995;105:31-57
   PubMed Web of Science ®Google Scholar
• Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001;248:91-101
   PubMed Web of Science ®Google Scholar
• Helguera G, Morrison SL, Penichet ML. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin Immunol 2002;105:233-46
   PubMed Web of Science ®Google Scholar
• Davis CB, Gillies SD. Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 2003;52:297-308
   PubMed Web of Science ®Google Scholar
• Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514
   PubMed Web of Science ®Google Scholar
• Grimm EA, Owen-Schaub L. The IL-2 mediated amplification of cellular cytotoxicity. J Cell Biochem 1991;45:335-9
   PubMed Web of Science ®Google Scholar
• Espinoza-Delgado I, Bosco MC, Musso T, et al. Interleukin-2 and human monocyte activation. J Leukoc Biol 1995;57:13-9
   PubMed Web of Science ®Google Scholar
• Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988;168:1419-41
   PubMed Web of Science ®Google Scholar
• Kasahara T, Djeu JY, Dougherty SF, Oppenheim JJ. Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor. J Immunol 1983;131:2379-85
   PubMed Web of Science ®Google Scholar
• Wall L, Burke F, Barton C, et al. IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitro Clin. Cancer Res 2003;9:2487-96
   Web of Science ®Google Scholar
• Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143:1210-4
   PubMed Web of Science ®Google Scholar
• Varesio L, Blasi E, Thurman GB, et al. Potent activation of mouse macrophages by recombinant interferon-γ. Cancer Res 1984;44:4465-9
   PubMed Web of Science ®Google Scholar
• Djeu JY, Stocks N, Zoon K, et al. Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J Exp Med 1982;156:1222-34
   PubMed Web of Science ®Google Scholar
• Rosa FM. Regulation of HLA-DR gene by IFN-gamma. Transcriptional and post-transcriptional control. J Immunol 1998;140:1660-4
   Google Scholar
• Albertini MR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 1997;3:1277-88
   PubMed Web of Science ®Google Scholar
• Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006;175:57-62
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307-19
   PubMed Web of Science ®Google Scholar
• Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704
   PubMed Web of Science ®Google Scholar
• Penichet ML, Harvill ET, Morrison SL. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. J Interferon Cytokine Res 1998;18:597-607
   PubMed Web of Science ®Google Scholar
• Hornick JL, Khawli LA, Hu P, et al. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 1997;89:4437-47
   PubMed Web of Science ®Google Scholar
• Heuser C, Ganser M, Hombach A, et al. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells. Br J Cancer 2003;89:1130-9
   PubMed Web of Science ®Google Scholar
• Harvill ET, Morrison SL. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1995;1:95-105
   PubMedGoogle Scholar
• Dangl JL, Wensel TG, Morrison SL, et al. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988;7:1989-94
   PubMed Web of Science ®Google Scholar
• Phillips ML, Tao MH, Morrison SL, Schumaker VN. Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol Immunol 1994;31:1201-10
   PubMed Web of Science ®Google Scholar
• Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989;143:2595-601
   PubMed Web of Science ®Google Scholar
• Harvill ET, Fleming JM, Morrison SL. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J Immunol 1996;157:3165-70
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Phillips H, Schindler J, et al. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 1987;47:5725-32
   PubMed Web of Science ®Google Scholar
• Liu SJ, Sher YP, Ting CC, et al. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins. Blood 1998;92:2103-12
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12
   PubMed Web of Science ®Google Scholar
• Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001;12(Suppl 1):S23-28
   PubMedGoogle Scholar
• Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies 2001;10:43-9
   PubMedGoogle Scholar
• Helguera G, Rodriguez JA, Penichet ML. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol Cancer Ther 2006;5:1029-40
   PubMed Web of Science ®Google Scholar
• Najjam S, Mulloy B, Theze J, et al. Further characterization of the binding of human recombinant interleukin 2 to heparin and identification of putative binding sites. Glycobiology 1998;8:509-16
   PubMed Web of Science ®Google Scholar
• Wrenshall LE, Platt JL, Stevens ET, et al. Propagation and control of T cell responses by heparan sulfate-bound IL-2. J Immunol 2003;170:5470-4
   PubMed Web of Science ®Google Scholar
• Shi M, Xie Z, Feng J, et al. A recombinant anti-erbB2, scFv-Fc-IL-2 fusion protein retains antigen specificity and cytokine function. Biotechnol Lett 2003;25:815-9
   PubMed Web of Science ®Google Scholar
• Shi M, Zhang L, Gu HT, et al. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo Acta Pharmacol. Sin 2007;28:1611-20
   Google Scholar
• Midulla M, Verma R, Pignatelli M, et al. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res 2000;60:164-9
   PubMed Web of Science ®Google Scholar
• Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005;9:491-500
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002;99:1659-65
   PubMed Web of Science ®Google Scholar
• Curigliano GS, De Pas T, Noberasco C, et al. Compositions and methods for treatment of angiogenesis in pathological lesions. 2007 ASCO Annual Meeting Proceedings Part I. J Clinical Oncol 2007;25:3057
   Google Scholar
• Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51
   PubMed Web of Science ®Google Scholar
• Hilkens J, Vos HL, Wesseling J, et al. Is episialin/MUC1 involved in breast cancer progression? Cancer Lett 1995;90:27-33
   PubMed Web of Science ®Google Scholar
• Von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997;151:1123-30
   PubMed Web of Science ®Google Scholar
• Heuser C, Guhlke S, Matthies A, et al. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells. Int J Cancer 2004;110:386-94
   PubMed Web of Science ®Google Scholar
• Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33
   PubMed Web of Science ®Google Scholar
• Delgado J, Matutes E, Morilla AM, et al. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol 2003;120:754-9
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lan Y, Williams S, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 2005;105:3972-8
   PubMed Web of Science ®Google Scholar
• Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-40
   PubMed Web of Science ®Google Scholar
• Zhang X, Feng J, Ye X, et al. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer. Gynecol Oncol 2006;103:848-52
   PubMed Web of Science ®Google Scholar
• Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol 1986;102:688-96
   PubMed Web of Science ®Google Scholar
• Kendra K, Gan J, Ricci M, et al. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother 1999;48:219-29
   PubMed Web of Science ®Google Scholar
• Neal ZC, Yang JC, Rakhmilevich AL, et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 2004;10:4839-47
   PubMed Web of Science ®Google Scholar
• Becker JC, Pancook JD, Gillies SD, et al. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996;183:2361-6
   PubMed Web of Science ®Google Scholar
• Becker JC, Varki N, Gillies SD, et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996;93:7826-31
   PubMed Web of Science ®Google Scholar
• Becker JC, Varki N, Gillies SD, et al. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996;98:2801-4
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Dreier T, et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91:1706-15
   PubMed Web of Science ®Google Scholar
• Osenga KL, Hank JA, Albertini MR, et al. A Phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-9
   PubMed Web of Science ®Google Scholar
• King DM, Albertini MR, Schalch H, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004;22:4463-73
   PubMed Web of Science ®Google Scholar
• Poczatek RB, Myers RB, Manne U, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999;162:1462-6
   PubMed Web of Science ®Google Scholar
• Pauli C, Munz M, Kieu C, et al. Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett 2003;193:25-32
   PubMed Web of Science ®Google Scholar
• Shetye J, Christensson B, Rubio C, et al. The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res 1989;9:395-404
   PubMed Web of Science ®Google Scholar
• Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24
   PubMed Web of Science ®Google Scholar
• De Boer CJ, Van Krieken JH, Janssen-Van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999;188:201-6
   PubMed Web of Science ®Google Scholar
• Xiang R, Lode HN, Dolman CS, et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997;57:4948-55
   PubMed Web of Science ®Google Scholar
• Xiang R, Lode HN, Gillies SD, Reisfeld RA. T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 1999;163:3676-83
   PubMed Web of Science ®Google Scholar
• Imboden M, Murphy KR, Rakhmilevich AL, et al. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 2001;61:1500-7
   PubMed Web of Science ®Google Scholar
• Ruehlmann JM, Xiang R, Niethammer AG, et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001;61:8498-503
   PubMed Web of Science ®Google Scholar
• Holden SA, Lan Y, Pardo AM, et al. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001;7:2862-9
   PubMed Web of Science ®Google Scholar
• Ko YJ, Bubley GJ, Weber R, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a Phase I trial in patients with prostate cancer. J Immunother 2004;27:232-9
   PubMed Web of Science ®Google Scholar
• Connor JP, Felder M, Hank J, et al. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 2004;27:211-9
   PubMed Web of Science ®Google Scholar
• Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146:3074-2081
   PubMed Web of Science ®Google Scholar
• Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68
   PubMed Web of Science ®Google Scholar
• Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995;154:5071-9
   PubMed Web of Science ®Google Scholar
• Gately MK, Gubler U, Brunda MJ, et al. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1994;1:187-96
   PubMedGoogle Scholar
• Voest EE, Kenyon BM, O'reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6
   PubMed Web of Science ®Google Scholar
• Wong GH, Clark-Lewis I, Harris AW, Schrader JW. Effect of cloned interferon-gamma on expression of H-2 and Ia antigens on cell lines of hemopoietic, lymphoid, epithelial, fibroblastic and neuronal origin. Eur J Immunol 1984;14:52-6
   PubMed Web of Science ®Google Scholar
• Arenberg DA, Kunkel SL, Polverini PJ, et al. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981-92
   PubMed Web of Science ®Google Scholar
• Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000;60:1111-6
   PubMed Web of Science ®Google Scholar
• Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Peng LS, Penichet ML, Morrison SL. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 1999;163:250-8
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997;15:35-40
   PubMed Web of Science ®Google Scholar
• Garnier P, Gibbs RV, Rider CC. A role for chondroitin sulphate B in the activity of interleukin 12 in stimulating γ-interferon secretion. Immunol Lett 2003;85:53-8
   PubMed Web of Science ®Google Scholar
• Hasan M, Najjam S, Gordon MY, et al. IL-12 is a heparin-binding cytokine. J Immunol 1999;162:1064-70
   PubMed Web of Science ®Google Scholar
• Peng LS, Penichet ML, Dela Cruz JS, et al. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). J Interferon Cytokine Res 2001;21:709-20
   PubMed Web of Science ®Google Scholar
• Helguera G, Rodriguez JA, Daniels TR, Penichet ML. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunol Immunother 2007;56:1507-12
   PubMed Web of Science ®Google Scholar
• Halin C, Gafner V, Villani ME, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003;63:3202-10
   PubMed Web of Science ®Google Scholar
• Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-9
   PubMed Web of Science ®Google Scholar
• Gafner V, Trachsel E, Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 2006;119:2205-12
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Leprini A, Allemanni G, et al. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem 1992;267:24689-92
   PubMed Web of Science ®Google Scholar
• Lo KM, Lan Y, Lauder S, et al. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother 2007;56:447-57
   PubMed Web of Science ®Google Scholar
• Heuser C, Diehl V, Abken H, Hombach A. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-γ secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. Int J Cancer 2003;106:545-52
   PubMed Web of Science ®Google Scholar
• Makabe K, Asano R, Ito T, et al. Tumor-directed lymphocyte-activating cytokines: refolding-based preparation of recombinant human interleukin-12 and an antibody variable domain-fused protein by additive-introduced stepwise dialysis. Biochem Biophys Res Commun 2005;328:98-105
   PubMed Web of Science ®Google Scholar
• Steele N, Haigh R, Knowles G, Mackean M. Carcinoembryonic antigen (CEA) testing in colorectal cancer follow up: what do patients think? Postgrad Med J 2007;83:612-4
   PubMed Web of Science ®Google Scholar
• Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006;16:126-33
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43
   PubMed Web of Science ®Google Scholar
• Ji Q, Gondek D, Hurwitz AA. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J Immunol 2005;175:1456-63
   PubMed Web of Science ®Google Scholar
• Ryu JK, Swann S, Leveque F, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective Phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys 2007;67:643-50
   PubMed Web of Science ®Google Scholar
• Zimmer BM, Berdel WE, Ludwig WD, et al. Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies. Leuk Res 1993;17:277-83
   PubMed Web of Science ®Google Scholar
• Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo Int. J Cancer 1996;67:54-62
   PubMed Web of Science ®Google Scholar
• Ruef C, Coleman DL. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990;12:41-62
   PubMedGoogle Scholar
• Daniels TR, Delgado T, Rodriguez JA, et al. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006;121:144-58
   PubMed Web of Science ®Google Scholar
• Dreier T, Lode HN, Xiang R, et al. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities. Bioconjug Chem 1998;9:482-9
   PubMed Web of Science ®Google Scholar
• Batova A, Kamps A, Gillies SD, et al. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro Clin. Cancer Res 1999;5:4259-63
   Web of Science ®Google Scholar
• Metelitsa LS, Gillies SD, Super M, et al. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002;99:4166-73
   PubMed Web of Science ®Google Scholar
• Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007;67:4940-8
   PubMed Web of Science ®Google Scholar
• Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000;165:5112-21
   PubMed Web of Science ®Google Scholar
• Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci USA 1989;86:4240-3
   PubMed Web of Science ®Google Scholar
• Hazama M, Mayumi-Aono A, Asakawa N, et al. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2. Vaccine 1993;11:629-36
   PubMed Web of Science ®Google Scholar
• Nakao M, Hazama M, Mayumi-Aono A, et al. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. J Infect Dis 1994;169:787-91
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Mclain D, Olencki T, et al. Interleukin-2: use in solid tumors. Stem Cells 1993;11:26-32
   PubMed Web of Science ®Google Scholar
• Majhail NS, Wood L, Elson P, et al. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study. Clin Genitourin Cancer 2006;5:50-6
   PubMed Web of Science ®Google Scholar
• Zabrecky JR, Lam T, Mckenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-20
   PubMed Web of Science ®Google Scholar
• Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001;7:2703-11
   PubMed Web of Science ®Google Scholar
• Disis ML, Gralow JR, Bernhard H, et al. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996;156:3151-8
   PubMed Web of Science ®Google Scholar
• Dela Cruz JS, Lau SY, Ramirez EM, et al. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 2003;21:1317-26
   PubMed Web of Science ®Google Scholar
• Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334:255-8
   PubMed Web of Science ®Google Scholar
• Yip YL, Ward RL. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 2002;50:569-87
   PubMed Web of Science ®Google Scholar
• Dela Cruz JS, Morrison SL, Penichet ML. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine 2005;23:4793-803
   PubMed Web of Science ®Google Scholar
• Hiltbold EM, Vlad AM, Ciborowski P, et al. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000;165:3730-41
   PubMed Web of Science ®Google Scholar
• Dela Cruz JS, Trinh KR, Chen HW, et al. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol 2006;43:667-76
   PubMed Web of Science ®Google Scholar
• Morris P, Shaman J, Attaya M, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551-4
   PubMed Web of Science ®Google Scholar
• Wigginton JM, Komschlies KL, Back TC, et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996;88:38-43
   PubMed Web of Science ®Google Scholar
• Ohe Y, Podack ER, Olsen KJ, et al. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int J Cancer 1993;53:432-7
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Abe J, Tsunoda R, et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996;56:1828-33
   PubMed Web of Science ®Google Scholar
• Hill HC, Conway TF Jr, Sabel MS, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002;62:7254-63
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lan Y, Brunkhorst B, et al. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol Immunother 2002;51:449-60
   PubMed Web of Science ®Google Scholar
• Helguera G, Dela Cruz JS, Lowe C, et al. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine 2006;24:304-16
   PubMed Web of Science ®Google Scholar
• Schanzer JM, Baeuerle PA, Dreier T, Kufer P. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells. Cancer Immun 2006;6:4
   PubMedGoogle Scholar
• Schanzer JM, Fichtner I, Baeuerle PA, Kufer P. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. J Immunother 2006;29:477-88
   PubMed Web of Science ®Google Scholar
• Hombach A, Heuser C, Abken H. Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer 2005;115:241-7
   PubMed Web of Science ®Google Scholar
• Raymond JS, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer 2006;94:1745-50
   PubMed Web of Science ®Google Scholar
• Ueno M, Muto T, Oya M, et al. Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003;8:162-7
   PubMedGoogle Scholar